Two randomized studies demonstrated that Nab-P produces a significantly higher overall response rate (ORR), longer Time to Progression (TTP) and greater overall survival (OS) in ABC pts treated with second-line or greater therapy. The improved safety and efficacy profile for Nab-P compared with solvent-based taxanes suggests that Nab-P may be particularly useful in older patients. A post-hoc analysis showed that weekly Nab-P (wNab-P) was safe and more efficacious in comparison to the q3w schedule and with solvent-based taxanes in older patients with ABC. Aim of the present analysis is to describe the use of Nab-P in the elderly (≥ 65 years) population registered in the GIM-13 AMBRA study.
Nab-paclitaxel (Nab-P) in patients (pts) with HER2-ve advanced breast cancer (ABC): A focus on the elderly— Preliminary results of the GIM-13 AMBRA study
Clara Natoli;
2018-01-01
Abstract
Two randomized studies demonstrated that Nab-P produces a significantly higher overall response rate (ORR), longer Time to Progression (TTP) and greater overall survival (OS) in ABC pts treated with second-line or greater therapy. The improved safety and efficacy profile for Nab-P compared with solvent-based taxanes suggests that Nab-P may be particularly useful in older patients. A post-hoc analysis showed that weekly Nab-P (wNab-P) was safe and more efficacious in comparison to the q3w schedule and with solvent-based taxanes in older patients with ABC. Aim of the present analysis is to describe the use of Nab-P in the elderly (≥ 65 years) population registered in the GIM-13 AMBRA study.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
